Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.22
−$0.11 · -2.06%
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Latest quote
$5.22
−$0.11 · -2.06%
After-hours
$5.22
$0.00 · 0.00%
Sep 11, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Day range
Current $5.22
52-week range
Current $5.22
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
62
Bullish
Risk
80
High Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Day range
Current $5.22
52-week range
Current $5.22
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.19M USD | 3.95M USD | 15.53M USD | 13.91M USD | 4.36M USD |
| Cost of goods sold | 930K USD | — | — | — | — |
| Gross profit | 1.26M USD | 3.95M USD | 15.53M USD | 13.91M USD | 4.36M USD |
| Research and development | 69.45M USD | 70.27M USD | 73.04M USD | 85.08M USD | 104.15M USD |
| Selling, general, and administrative | 20.72M USD | 22.83M USD | 30.62M USD | 26.41M USD | 28.53M USD |
| Operating expenses | 89.24M USD | 93.1M USD | 103.66M USD | 111.49M USD | 132.68M USD |
| Interest income | 2.16M USD | 1.67M USD | 1.24M USD | 1.64M USD | 132K USD |
| Depreciation and amortization | 930K USD | 2.62M USD | 3.07M USD | 3.68M USD | 3.78M USD |
| Operating income | −87.99M USD | −89.15M USD | −88.13M USD | −97.58M USD | −128.32M USD |
| Net income | −24.19M USD | −131.21M USD | −87.68M USD | −96.05M USD | −128.33M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.00
283.14% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 19, 2024 | 1:25 | — | — |
Effective Aug 19, 2024
1:25
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI544.7K0.00%2.3T USD0.03%$376.27+0.81%
Vanguard Extended Market ETFVXF197.85K0.00%93.7B USD0.05%$237.76+0.68%
iShares Micro-Cap ETFIWC89.76K0.01%1.44B USD0.60%$190.84+0.39%
U.S. Micro Cap Portfolio ETFDFMC44.39K0.00%7.67B USD0.43%$59.13+0.67%
Dimensional - US Small Cap ETFDFAS14.98K0.00%15.39B USD0.26%$80.52+0.64%
Dimensional - US Core Equity 2 ETFDFAC9.89K0.00%48.76B USD0.17%$45.16+0.71%
Avantis U.S. Small Cap Equity ETFAVSC7.61K—3.07B USD0.25%$71.48+0.53%
Dimensional - US Sustainability Core 1 ETFDFSU6.12K0.00%2.33B USD0.15%$47.79+0.82%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Core Equity 2 ETFDFACAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Sustainability Core 1 ETFDFSUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
